RxDoctor Payments DataLook up a doctor →

Benjamin Jacobs, MD

Internal Medicine · Media, PANPI 1578790341

Payments from drug & device makers

$226,908in general payments, 2019–2025

Across 407 payments — averaging $557.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mirati Therapeutics, Inc.$162K
  • Amgen$47K
  • AstraZeneca$4K
  • Verastem, Inc.$2K
  • G1 Therapeutics, Inc.$2K
  • Blueprint Medicines Corporation$1K
  • plus $9K from 52 others

What the payments were for

  • Consulting fees$2,95819%
  • Speaking & faculty fees$5,18033%
  • Food & beverage$7,52347%
  • Education$2101%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Mirati Therapeutics, Inc.35$162,385
Amgen5$46,729
AstraZeneca(2 entities)49$4,018
Verastem, Inc.3$2,052
G1 Therapeutics, Inc.1$1,500
Blueprint Medicines Corporation3$1,498
Seagen Inc.4$1,312
Rigel Pharmaceuticals, Inc.2$1,019
Johnson & Johnson(2 entities)27$603
Novartis28$579
E.r. Squibb & Sons, L.L.C.23$478
Incyte Corporation21$395
Daiichi Sankyo Inc.18$378
AbbVie20$369
Pfizer20$356
Merck13$255
Gilead(2 entities)11$218
Eisai Inc.10$217
Bayer9$184
Bristol Myers Squibb7$163
Servier Pharmaceuticals LLC4$159
Karyopharm Therapeutics Inc.5$147
Sobi, Inc7$139
Lilly USA, LLC6$125
Tempus AI, Inc5$114
Pharmacyclics LLC, An Abbvie Company6$105
Sanofi4$88
EMD Serono, Inc.4$85
Acrotech Biopharma Inc.3$84
Genentech USA, Inc.4$84
Takeda Pharmaceuticals U.S.A., Inc.4$79
Array Biopharma Inc1$75
Beone Medicines USA, Inc.3$73
GSK3$70
Boehringer Ingelheim3$67
Genmab U.S., Inc.3$67
Pharmacosmos Therapeutics Inc.3$60
Regeneron Healthcare Solutions, Inc.2$56
Recordati_rare_diseases_inc.2$54
Astellas Pharma US Inc2$42
Jazz Pharmaceuticals Inc.2$41
Tersera Therapeutics LLC2$40
Tesaro, Inc.2$38
Lexicon Pharmaceuticals, Inc.2$35
Clovis Oncology, Inc.3$29
Taiho Oncology, Inc.1$26
Ipsen Biopharmaceuticals, Inc1$25
Stemline Therapeutics Inc.1$23
Syndax Pharmaceuticals, Inc.1$22
Beigene USA, Inc.1$21
Dova Pharmaceuticals1$21
Myriad Genetic Laboratories, Inc.1$21
Springworks Therapeutics, Inc.1$20
AMAG Pharmaceuticals, Inc.1$17
Foundation Medicine, Inc.1$16
Teva Pharmaceuticals USA, Inc.1$12
Advanced Accelerator Applications1$12
Agios Pharmaceuticals, Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$226,908 in reported general payments places this provider in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$5,664,009
Medicare patients
669
Services billed
230,329

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CalquenceAcalabrutinib Maleate43$654,363
RevlimidLenalidomide24$505,434
JakafiRuxolitinib Phosphate16$297,797
TagrissoOsimertinib Mesylate11$187,235
EliquisApixaban38$33,070
XareltoRivaroxaban14$21,844
Deferasirox16$9,707
Abiraterone Acetate13$3,274
Anastrozole72$2,030
Voriconazole12$1,577
Oxycodone Hcl96$1,511
Hydroxyurea40$1,108
Ondansetron OdtOndansetron38$503
Dexamethasone19$393
Lorazepam19$260

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaCalquence, Tagrisso$4,018$841,59854 claims
Bristol Myers SquibbRevlimid$163$505,43424 claims
Incyte CorporationJakafi$395$297,79716 claims
PfizerEliquis$356$33,07038 claims
Johnson & JohnsonXarelto$603$21,84414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Media

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →